17.04.2021 | ASO Author Reflections
ASO Author Reflections: Gastric Cancer with Peritoneal Metastasis: Are Some Patients Surgical Candidates?
verfasst von:
Jose M. Pimiento, MD, Sean P. Dineen, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Excerpt
Gastric cancer is a leading cause of cancer-related mortality worldwide. Peritoneal metastases occur in approximately 30% of patients and can contribute to the overall poor prognosis for patients. Due to the occult nature of many peritoneal implants, diagnostic laparoscopy is considered standard for all but the earliest gastric cancers. In patients with gastric cancer and peritoneal metastases (GC/PM), systemic chemotherapy has been considered the standard treatment, although the overall survival remains poor at approximately 12 months for such patients.
1 Surgical approaches, including intraperitoneal delivery of chemotherapy, are attractive to potentially overcome this poor prognosis; however, initial investigations into surgical resection were associated with high morbidity and mortality rates. Thus, for many years, the presence of peritoneal metastases has been considered a contraindication to extirpative surgery due to the typically poor outcomes. In the Landmark Series paper presented in this issue, we discuss the important studies that address the role of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for patients with GC/PM.
2 …